Immunome Receives FDA Clearance For Its Investigational New Drug Application For IM-1340 To Treat Advanced Solid Tumors

Immunome to Present Initial First-in-Human Clinical Data for IM-1021 at ASH 2026

Immunome, Inc. announced it will present initial first-in-human clinical data from its ongoing Phase 1 study of IM-1021, an ROR1-targeted antibody-drug conjugate, at the 68th American Society of Hematology Annual Meeting.

Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat

Immunome, Inc. announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) for varegacestat, an investigational gamma secretase inhibitor for treating adults with desmoid tumors.

Wedbush Reiterates Outperform on Immunome, Maintains $35 Price Target

Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026

Immunome, Inc. presented new clinical data for its investigational gamma secretase inhibitor, varegacestat, at the 2026 European Society for Medical Oncology (ESMO) Congress.

Analyst Initiates Coverage on Immunome

An analyst has initiated research coverage on Immunome (IMNM) as part of a broader inaugural report covering thirteen biotechnology companies.

William Blair Initiates Coverage On Immunome with Outperform Rating

William Blair analyst Alethia Young initiates coverage on Immunome (NASDAQ:IMNM) with a Outperform rating.